Cephalosporin + beta-lactamase inhibitor
Ceftolozane with tazobactam
Brand names: Zerbaxa
Adult dose
Dose: 1g/0.5g IV q8h (or 2g/1g for nosocomial pneumonia)
Route: IV
Frequency: q8h
Clinical pearls
- NICE TA836: complicated UTI, intra-abdominal, hospital-acquired pneumonia (anti-pseudomonal)
- BSAC / UKHSA AMR — restricted
- Specialist microbiology approval
Contraindications
- Severe beta-lactam hypersensitivity
Side effects
- GI upset
- Hypersensitivity
- Hepatic enzyme elevation
- C. difficile
Interactions
- Limited
Monitoring
- Renal
- C. diff
- Microbiological response
Reference: BNF; NICE TA836; BSAC; UKHSA AMR; SmPC; https://bnf.nice.org.uk/drugs/ceftolozane-with-tazobactam/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- C-Peptide to Glucose Ratio · Diabetes Classification
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023